CELZ - Creative Medical Technology Holdings, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CELZ

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

NASDAQ

$1.11

▲ UP 4.72% (0.05)

KEY STATISTICS

Market Cap$2.88 M

52w High$6.25

52w Low$0.62

Dividend Yield—

Frequency—

P/E-0.52

Volume150.80K

Shares Out.2.58M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Timothy Warbington

COMPENSATION 2026

Salary$339,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$247,500

Total$587,220

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 6, 2015

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 6, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2023-06-12	Reverse	1:10
2021-11-10	Reverse	1:500
2020-02-03	Reverse	1:150

PRICE

$1.11 ▲ UP 4.72% (+$0.05)

OVERLAYS

About Creative Medical Technology Holdings, Inc.

https://www.creativemedicaltechnology.com ↗

Creative Medical Technology Holdings, Inc. is a Phoenix-based biotech company developing adult stem cell treatments for immunology, urology, orthopedics, and neurology, including therapies for erectile dysfunction, infertility, back pain, stroke, ...

INDUSTRY

Biotechnology

A PRODUCT CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. IS KNOWN FOR

CELZ-201 (Olastrocel)

CELZ-201 (olastrocel) is an allogeneic, perinatal tissue-derived cell therapy under the AlloStem® platform, in clinical trials for degenerative disc disease and Type 1 diabetes, with positive interim data and FDA Fast Track designation.